These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23918722)

  • 21. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
    Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
    Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse effects and safety profile of perampanel: a review of pooled data.
    Rugg-Gunn F
    Epilepsia; 2014 Jan; 55 Suppl 1():13-5. PubMed ID: 24400692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
    Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
    Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis.
    Khan N; Shah D; Tongbram V; Verdian L; Hawkins N
    Curr Med Res Opin; 2013 Aug; 29(8):1001-13. PubMed ID: 23659562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perampanel: as adjunctive therapy in patients with partial-onset seizures.
    Plosker GL
    CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.
    Ettinger AB; LoPresti A; Yang H; Williams B; Zhou S; Fain R; Laurenza A
    Epilepsia; 2015 Aug; 56(8):1252-63. PubMed ID: 26140524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
    Laurenza A; Yang H; Williams B; Zhou S; Ferry J
    Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of perampanel in different disorders and doses: A meta-analysis.
    Liu P; Zhu Z; Wu H
    Seizure; 2023 Mar; 106():22-28. PubMed ID: 36724644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
    Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
    Strzelczyk A; Willems LM; Willig S; Rosenow F; Bauer S
    Expert Rev Clin Pharmacol; 2015; 8(6):733-40. PubMed ID: 26436331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.
    Tian X; Yuan M; Zhou Q; Wang X
    Expert Opin Pharmacother; 2015; 16(12):1755-67. PubMed ID: 26165169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability and safety of perampanel: two randomized dose-escalation studies.
    Krauss GL; Bar M; Biton V; Klapper JA; Rektor I; Vaiciene-Magistris N; Squillacote D; Kumar D
    Acta Neurol Scand; 2012 Jan; 125(1):8-15. PubMed ID: 21883097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.